Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

3 High Dividend Stocks to Buy for Safety in Your Portfolio

By Chris Lau, InvestorPlace Contributor

Dividend stocks give investors a source of steady money. These 3 stocks are also 'safety' stocks -- so their dividends aren't going anywhere.

There’s More to Like About MSFT Stock Than a Likely Dividend Bump

By Chris Lau, InvestorPlace Contributor

Microsoft is generating tremendous cash flow growth and higher profit margins. Higher dividends for MSFT are on the way, too.

7 Biotech Stocks to Buy Now

By Chris Lau, InvestorPlace Contributor

Biotech companies are recovering nicely this year. With a quarter left to go, the upside potential is high for those biotech stocks that dipped recently.

Teva Wins Approval From FDA for Blockbuster Migraine Drug

By Chris Lau, InvestorPlace Contributor

The markets are ignoring the potential sales growth for Teva's migraine drug. Value investors should look at Teva stock now.

Cronos Gets Bigger As It Partners With Ginkgo Bioworks

By Chris Lau, InvestorPlace Contributor

Cronos is expanding its addressable market by entering into a joint partnership with Ginkgo Bioworks, which is good news for CRON stock.

Load More